Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Making Ramadhan Fasting a Safer Experience With Technology Study
Brief Summary: Type 2 diabetes mellitus (T2DM) is a chronic condition that is one of the major causes of illness, disability, and death in Malaysia with an increasing prevalence. Despite the best effort, only 1 in 3 patients ever meet their HbA1c goal. In most patients with type 2 diabetes, the use of oral anti-diabetics is a mainstay in therapy. However, there is a risk of hypoglycaemia in most patients taking these drugs. This is especially important in T2DM Muslims wishing to fast during Ramadan as the dietary pattern changes to one large meal at sunset called 'Iftaar' and a light meal before dawn called 'Sahur'. Most Muslims will generally consume large quantities of fried and sugary foods when they break their fast or during the night. Given the importance and public health significance of poor diabetes management and its associated risk especially during Ramadan, the investigators aim to test the intervention of using remote monitoring within community provider practice for patients with T2DM. The investigators hypothesize that the combined use of a mobile enable glucometer which can directly feedback the patients glycaemic levels to the physicians will reduce and even eliminate the occurrence of hypoglycaemia whilst ensuring that patients remain euglycaemic throughout the whole Ramadan month.


Options:
A: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin phosphate, Drug: Metformin | Arm Label: Sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin phosphate; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Comparator: Sulfonylurea; Assigned to Arm(s): Sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea
B: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
D: Arm Label: 14 days continuous glucose monitoring; Type: OTHER; Interventions: Other: Control period, Dietary Supplement: D-allulose period | Intervention Type: OTHER; Name: Control period; Assigned to Arm(s): 14 days continuous glucose monitoring | Intervention Type: DIETARY_SUPPLEMENT; Name: D-allulose period; Assigned to Arm(s): 14 days continuous glucose monitoring

Answer: C